Reference entry · Melanocortin receptor agonist
PT-141
Also known as: Bremelanotide · Vyleesi (approved drug name)
- Class
- Melanocortin receptor agonist
- Size
- 7 amino acids (cyclic heptapeptide)
- Primary targets (literature)
- MC3R, MC4R (melanocortin receptors)
- Regulatory context
- FDA-approved as Vyleesi for a defined indication. Catalog PT-141 is research-use-only unless explicitly documented as pharmaceutical product.
Overview
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist derived from melanocortin peptide chemistry. It has published phase 3 clinical literature for central sexual-arousal pathways and is FDA-approved as Vyleesi — distinct from catalog RUO material without pharmaceutical documentation.
Mechanism in research literature
Melanocortin receptor agonism at MC3R and MC4R in central nervous system research models, with downstream effects on arousal-related neurocircuitry studied in formal trials and preclinical pharmacology.
Common research focus areas
- Melanocortin receptor pharmacology (MC3R/MC4R)
- Phase 3 bremelanotide trial endpoints
- Relationship to melanotan II precursor chemistry
- Catalog vs. pharmaceutical material distinction
Full literature roundup
Read the cited research summary
A melanocortin receptor agonist with published phase 3 clinical literature. Central pharmacology, bremelanotide evidence, and catalog material quality.
PT-141 research roundup · 7 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.